Market Currents
Geron's (GERN -7.9%) board acknowledges receiving a letter from BioTime (BTX -3.3%) offering to...
-
Friday, October 19, 2012, 12:23 PM ETGeron's (GERN -7.9%) board acknowledges receiving a letter from BioTime (BTX -3.3%) offering to buy its stem cell assets, saying it will review and act in a manner that it believes will be in the best interests of GERN's stockholders. The board adds that it's been considering a number of alternatives since its announcement earlier this month that it was discontinuing its stem cell research and development programs.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
